研究者詳細 - 平沢　晃

論文 - 平沢　晃

分割表示 403 件中 261 - 280 件目／全件表示 >>

牧田和也, 松村聡子, 堀場裕子, 平沢晃, 小川真里子, 弟子丸亮太, 柳本茂久, 高松潔, 青木大輔, 吉村泰典

日本女性医学学会雑誌 19 ( 1 ) 18-23 - 24 2011年

記述言語：日本語出版者・発行元：(一社)日本女性医学学会

(目的)エストロゲン低下を主因とする種々の退行期疾患の予防と早期治療を指向した当科「健康維持外来」におけるホルモン補充療法(HRT)施行例について、これまで得られたデータを再検証する。(対象・方法)1991年4月から2008年12月末までに当外来を受診した全初診患者3,210例の中から、臨床治験や男女混合ホルモンの筋肉注射を施行した例などを除き、HRTを6ヵ月以上に亘り連続して施行した経験のある症例および現在も施行中の計454例(開始時の平均年齢50.9歳)を調査対象とした。これらの症例のHRT開始時から既に終了している症例ではその時点までの、現在も継続中の症例については2009年6月末までの状況について、診療記録を下に調査を行った。(結果)454例中127例が現在HRTを施行中であり、最長継続例は約17年、10年以上継続している症例が37例存在した。HRTの主たる適応は、更年期不定愁訴が最も多かった。HRT開始時の投与方法は、エストロゲンと黄体ホルモンの併用持続投与が最も多かった。HRT開始時に経口剤を用いたものが353例であり、結合型エストロゲン剤が最も多かった。一方経皮吸収剤を用いた101例中85例がエストラジオールパッチ剤であった。HRTの施行終了に至った理由は、患者自らの申し出によるものが最も多かった。HRT施行時に発生した有害事象では、悪性腫瘍の発症が10例と最も多く、そのうち8例は乳癌であった。(考察)わが国においてHRTが本格的に導入されたのは、当外来が開設された時期とほぼ一致する。当外来においてHRTを施行し続けたことで、中高年女性のQuality of lifeの向上の一助となっていることを再確認した。(著者抄録)

researchmap

家系内の遺伝子検査が契機となり早期介入に至ったリンチ症候群の1例.

中村加奈子, 平沢晃, 赤羽智子, 鶴田智彦, 冨永英一郎, 阪埜浩司, 藤井多久磨, 進伸幸, 青木大輔, 吉村泰典

日本産科婦人科学会東京地方部会会誌 60 ( 2 ) 293-297 2011年

大腿骨頸部骨密度測定は腰椎骨骨密度測定の代用となり得るか？—当科健康維持外来受診者からの比較検討—

牧田和也, 松村聡子, 堀場裕子, 平沢晃, 小川真里子, 弟子丸亮太, 柳本茂久, 青木大輔

Osteoporosis Japan 19 ( 3 ) 481-483 - 483 2011年

記述言語：日本語出版者・発行元：ライフサイエンス出版(株)

健康維持外来初診患者に対して、腰椎骨骨密度と大腿骨頸部骨密度を同時に測定し、その両者の相関について検証した。健康維持外来を受診した初診患者205例を対象とした。腰椎骨骨密度値からみた診断では、第2から第4までの平均の骨密度値(L2-4BMD)から原発性骨粗霧症診断基準に従い診断すると、骨粗鬆症例が5例、骨量減少例が20例、骨量正常例が180例となるが測定部位全体の骨密度値(F-To BMD)からの診断と疾患名が一致したのは、骨粗鬆症例が5例中3例、骨量減少例20例中7例、骨量正常例180例中155例であった。大腿骨頸部骨密度値からみた診断では、F-To BMD値からの診断で、骨粗鬆症例が16例、骨量減少例が26例、骨量正常例が163例となるが、L2-4BMD値からの診断と疾患名が一致したのは、骨粗鬆症例が16例中3例、骨量減少例26例中7例、骨量正常例163例中155例であった。

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2011&ichushi_jid=J03021&link_issn=&doc_id=20110825190033&doc_link_id=%2Fai6ostoe%2F2011%2F001903%2F035%2F0481-0483%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fai6ostoe%2F2011%2F001903%2F035%2F0481-0483%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Atypical Polypoid Adenomyoma (APAM) of the Uterine: Relationship with Endometrial Cancer 査読

Kisu I, Banno K, Yanokura M, Kobayashi Y, Ueki A, Ono A, Masuda K, Yamagami W, Nomura H, HIRASAWA AKIRA, Susumu N, Aoki D

Journal of Cancer Therapy 2 ( 4 ) 458-462 2011年

Gynecological tumors in patients with Peutz-Jeghers syndrome (PJS). 査読

Ueki A, Kisu I, Banno K, Yanokura M, Masuda K, Kobayashi Y, HIRASAWA AKIRA, Aoki D

Open Journal of Genetics 1 ( 3 ) 65-69 2011年

ホルモン補充療法が腰椎骨密度に及ぼす長期的な効果の検討 -当科健康維持外来における10年継続投与例からの検証- .

牧田和也, 松村聡子, 堀場裕子, 平沢晃, 小川真里子, 弟子丸亮太, 柳本茂久, 高松潔, 青木大輔

Osteoporosis Japan 18 ( 3 ) 83-85 - 539 2011年

記述言語：日本語出版者・発行元：ライフサイエンス出版(株)

外来で更年期障害、卵巣欠落症状、閉経後骨粗鬆症を主な適応としてホルモン補充療法(HRT)を10年以上継続して施行した49例について、HRTの腰椎骨密度に対する長期的な効果を検討した。24例はHRTを終了したが25例は継続中である。HRT開始時に使用したエストロゲン製剤は結合型エストロゲン9割、経皮吸収剤(エストラジオール貼付剤)1割であった。HRT施行後18ヵ月迄は有意な増加傾向を示したが、その後はHRTを継続している限りプラトーになることが判明した。

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2010&ichushi_jid=J03021&link_issn=&doc_id=20100816080038&doc_link_id=%2Fai6ostoe%2F2010%2F001803%2F038%2F0537-0539%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fai6ostoe%2F2010%2F001803%2F038%2F0537-0539%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

ASSOCIATION BETWEEN COPY NUMBER VARIATIONS OF ESTROGEN MATABOLISM-RELATED GENE AND BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN OF JANANESE 査読

A. Hirasawa, K. Makita, T. Akahane, K. Banno, N. Susumu, D. Aoki

OSTEOPOROSIS INTERNATIONAL 21 ( 5 ) S722 - S723 2010年12月

MicroRNA and endometrial cancer: Roles of small RNAs in human tumors and clinical applications

Megumi Yanokura, Kouji Banno, Yusuke Kobayashi, Iori Kisu, Arisa Ueki, Asuka Ono, Kennta Masuda, Hiroyuki Nomura, Akira Hirasawa, Nobuyuki Susumu, Daisuke Aoki

ONCOLOGY LETTERS 1 ( 6 ) 935 - 940 2010年11月

記述言語：英語出版者・発行元：SPANDIDOS PUBL LTD

MicroRNAs (miRNAs) are small non-coding RNAs of approximately 22 base pairs that regulate the expression of genes by targeting messenger RNA with complementarity with the miRNA base sequence. Regulation of gene expression by miRNAs is crucial in cellular development and differentiation, and recent studies suggest a relationship between human diseases and the breakdown of gene silencing mechanisms induced by miRNA abnormalities. In particular, abnormal miRNA expression has been detected in various types of cancer and the target genes have been identified. These results indicate that miRNAs act in a manner equivalent to oncogenes or tumor suppressors. miRNAs may also serve as diagnostic biomarkers and therapeutic targets. In this review, we introduce the latest findings on miRNAs in human endometrial cancer, a common malignancy, and discuss the potential of miRNAs as biomarkers and targets for molecular therapy.

DOI： 10.3892/ol.2010.173

Web of Science

researchmap

遺伝性乳癌卵巣癌－婦人科の観点より－

平沢晃, 野村弘行, 青木大輔

乳癌の臨床 25 ( 5 ) 523-527 - 527 2010年11月

MicroRNA and endometrial cancer: Roles of small RNAs in human tumors and clinical applications (Review). 査読国際誌

Megumi Yanokura, Kouji Banno, Yusuke Kobayashi, Iori Kisu, Arisa Ueki, Asuka Ono, Kennta Masuda, Hiroyuki Nomura, Akira Hirasawa, Nobuyuki Susumu, Daisuke Aoki

Oncology letters 1 ( 6 ) 935 - 940 2010年11月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：SPANDIDOS PUBL LTD

DOI： 10.3892/ol.2010.173

Web of Science

PubMed

researchmap

腫瘍間質の遺伝子発現解析を用いた進行上皮性卵巣癌に対する新規バイオマーカーの探索

片岡史夫, 津田浩史, 野村弘行, 千代田達幸, 平沢晃, 冨永英一郎, 鈴木淳, 進伸幸, 青木大輔

日本分子腫瘍マーカー研究会プログラム・講演抄録 30回 52 - 53 2010年9月

女性の片頭痛

牧田和也, 平沢晃, 青木大輔

産婦人科治療 101 ( 2 ) 135-139 - 139 2010年8月

記述言語：日本語出版者・発行元：(株)永井書店

片頭痛は、周期的に認められる激しい頭痛発作により著しいquality of lifeの低下を招く一次性頭痛であり、女性においては月経周期、妊娠・出産・授乳、閉経といったライフステージに伴う女性ホルモンの変動との関連性が高く、とくに月経は最大のトリガーとされている。産婦人科外来に頭痛を主訴として来院する患者は少ないが、月経に関連して認められる頭痛などに着目することで、潜在的な片頭痛患者の掘り起こしが可能である。(著者抄録)

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2010&ichushi_jid=J00534&link_issn=&doc_id=20100813130006&doc_link_id=%2Faf2sftye%2F2010%2F010102%2F006%2F0135-0139%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Faf2sftye%2F2010%2F010102%2F006%2F0135-0139%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer. 国際誌

Ei-ichiro Tominaga, Hiroshi Tsuda, Tokuzo Arao, Sadako Nishimura, Masashi Takano, Fumio Kataoka, Hiroyuki Nomura, Akira Hirasawa, Daisuke Aoki, Kazuto Nishio

Gynecologic oncology 118 ( 2 ) 160 - 6 2010年8月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：ACADEMIC PRESS INC ELSEVIER SCIENCE

OBJECTIVES: The purpose of this study was to identify genes that predict progression-free survival (PFS) in advanced epithelial ovarian cancer (aEOC) receiving standard therapy. METHODS: We performed microarray analysis on laser microdissected aEOC cells. All cases received staging laparotomy and adjuvant chemotherapy (carboplatin+paclitaxel) as primary therapy. RESULTS: Microarray analysis identified 50 genes differentially expressed between tumors of patients with no evidence of disease (NED) or evidence of disease (ED) (p<0.001). Six genes (13%) were located at 8q24, and 9 genes (19.6%), at 20q11-13. The ratio of selected gene set/analyzed gene set in chromosomes 8 and 20 are significantly higher than that in other chromosome regions (6/606 vs. 32/13656, p=0.01) and (12/383 vs. 32/13656, p=1.3 x 10(-)(16)). We speculate that the abnormal chromosomal distribution is due to genomic alteration and that these genes may play an important role in aEOC and choose GNAS (GNAS complex locus, NM_000516) on 20q13 based on the p value and fold change. Genomic PCR of aEOC cells also showed that amplification of GNAS was significantly correlated with unfavorable PFS (p=0.011). Real-time quantitative RT-PCR analysis of independent samples revealed that high mRNA expression levels of the GNAS genes, located at chromosome 20q13, was significantly unfavorable indicators of progression-free survival (PFS). Finally, GNAS amplification was an independent prognostic factor for PFS. CONCLUSIONS: Our results suggest that GNAS gene amplification may be an independent, qualitative, and reproducible biomarker of PFS in aEOC.

DOI： 10.1016/j.ygyno.2010.03.010

Web of Science

PubMed

researchmap

無結紮手術（BiClamp，Ligasure，ハーモニック）－広汎子宮全摘出術におけるBiClamp使用の実際

進伸幸, 片岡史夫, 野村弘行, 平沢晃, 藤井多久磨, 青木大輔

産婦人科の実際 59 ( 8 ) 1195-1200 - 1200 2010年8月

A genome-wide association study identifies genetic variants in the CDKN2BAS locus associated with endometriosis in Japanese. 査読国際誌

Satoko Uno, Hitoshi Zembutsu, Akira Hirasawa, Atsushi Takahashi, Michiaki Kubo, Tomoko Akahane, Daisuke Aoki, Naoyuki Kamatani, Koichi Hirata, Yusuke Nakamura

Nature genetics 42 ( 8 ) 707 - 10 2010年8月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：NATURE PUBLISHING GROUP

Although the pathogenesis of endometriosis is not well understood, genetic factors have been considered to have critical roles in its etiology. Through a genome-wide association study and a replication study using a total of 1,907 Japanese individuals with endometriosis (cases) and 5,292 controls, we identified a significant association of endometriosis with rs10965235 (P = 5.57 x 10(-12), odds ratio = 1.44), which is located in CDKN2BAS on chromosome 9p21, encoding the cyclin-dependent kinase inhibitor 2B antisense RNA. By fine mapping, the SNP showing the strongest association was located in intron 16 of CDKN2BAS and was implicated in regulating the expression of p15, p16 and p14. A SNP, rs16826658, in the LD block including WNT4 on chromosome 1p36, which is considered to play an important role in the development of the female genital tract, revealed a possible association with endometriosis (P = 1.66 x 10(-6), odds ratio = 1.20). Our findings suggest that these regions are new susceptibility loci for endometriosis.

DOI： 10.1038/ng.612

Web of Science

PubMed

researchmap

A genome-wide association study identifies genetic variants in the CDKN2BAS locus associated with endometriosis in Japanese

Satoko Uno, Hitoshi Zembutsu, Akira Hirasawa, Atsushi Takahashi, Michiaki Kubo, Tomoko Akahane, Daisuke Aoki, Naoyuki Kamatani, Koichi Hirata, Yusuke Nakamura

NATURE GENETICS 42 ( 8 ) 707 - U88 2010年8月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：NATURE PUBLISHING GROUP

DOI： 10.1038/ng.612

Web of Science

researchmap

Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer 査読

Ei-ichiro Tominaga, Hiroshi Tsuda, Tokuzo Arao, Sadako Nishimura, Masashi Takano, Fumio Kataoka, Hiroyuki Nomura, Akira Hirasawa, Daisuke Aoki, Kazuto Nishio

GYNECOLOGIC ONCOLOGY 118 ( 2 ) 160 - 166 2010年8月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：ACADEMIC PRESS INC ELSEVIER SCIENCE

Objectives. The purpose of this study was to identify genes that predict progression-free survival (PFS) in advanced epithelial ovarian cancer (aEOC) receiving standard therapy.Methods. We performed microarray analysis on laser microdissected aEOC cells. All cases received staging laparotomy and adjuvant chemotherapy (carboplatin + paclitaxel) as primary therapy.Results. Microarray analysis identified 50 genes differentially expressed between tumors of patients with no evidence of disease (NED) or evidence of disease (ED) (p<0.001). Six genes (13%) were located at 8q24, and 9 genes (19.6%), at 20q11-13. The ratio of selected gene set/analyzed gene set in chromosomes 8 and 20 are significantly higher than that in other chromosome regions (6/606 vs. 32/13656, p 0.01) and (12/383 vs. 32/13656, p = 1.3 x 10(-16)). We speculate that the abnormal chromosomal distribution is due to genomic alteration and that these genes may play an important role in aEOC and choose GNAS (GNAS complex locus, NM__000516) on 20q13 based on the p value and fold change. Genomic PCR of aEOC cells also showed that amplification of GNAS was significantly correlated with unfavorable PFS (p = 0.011). Real-time quantitative RT-PCR analysis of independent samples revealed that high mRNA expression levels of the GNAS genes, located at chromosome 20q13, was significantly unfavorable indicators of progression-free survival (PFS). Finally, GNAS amplification was an independent prognostic factor for PFS.Conclusions. Our results suggest that GNAS gene amplification may be an independent, qualitative, and reproducible biomarker of PFS in aEOC. (C) 2010 Elsevier Inc. All rights reserved.

DOI： 10.1016/j.ygyno.2010.03.010

Web of Science

researchmap

Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer

Ei-ichiro Tominaga, Hiroshi Tsuda, Tokuzo Arao, Sadako Nishimura, Masashi Takano, Fumio Kataoka, Hiroyuki Nomura, Akira Hirasawa, Daisuke Aoki, Kazuto Nishio

GYNECOLOGIC ONCOLOGY 118 ( 2 ) 160 - 166 2010年8月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：ACADEMIC PRESS INC ELSEVIER SCIENCE

Objectives. The purpose of this study was to identify genes that predict progression-free survival (PFS) in advanced epithelial ovarian cancer (aEOC) receiving standard therapy.
Methods. We performed microarray analysis on laser microdissected aEOC cells. All cases received staging laparotomy and adjuvant chemotherapy (carboplatin + paclitaxel) as primary therapy.
Results. Microarray analysis identified 50 genes differentially expressed between tumors of patients with no evidence of disease (NED) or evidence of disease (ED) (p<0.001). Six genes (13%) were located at 8q24, and 9 genes (19.6%), at 20q11-13. The ratio of selected gene set/analyzed gene set in chromosomes 8 and 20 are significantly higher than that in other chromosome regions (6/606 vs. 32/13656, p 0.01) and (12/383 vs. 32/13656, p = 1.3 x 10(-16)). We speculate that the abnormal chromosomal distribution is due to genomic alteration and that these genes may play an important role in aEOC and choose GNAS (GNAS complex locus, NM__000516) on 20q13 based on the p value and fold change. Genomic PCR of aEOC cells also showed that amplification of GNAS was significantly correlated with unfavorable PFS (p = 0.011). Real-time quantitative RT-PCR analysis of independent samples revealed that high mRNA expression levels of the GNAS genes, located at chromosome 20q13, was significantly unfavorable indicators of progression-free survival (PFS). Finally, GNAS amplification was an independent prognostic factor for PFS.
Conclusions. Our results suggest that GNAS gene amplification may be an independent, qualitative, and reproducible biomarker of PFS in aEOC. (C) 2010 Elsevier Inc. All rights reserved.

DOI： 10.1016/j.ygyno.2010.03.010

Web of Science

researchmap

Relationship Between ABCF2 Expression and Response to Chemotherapy or Prognosis in Clear Cell Adenocarcinoma of the Ovary 査読

Hiroshi Tsuda, Kiyoshi Ito, Nobuo Yaegashi, Akira Hirasawa, Tamotsu Sudo, Tsunekazu Kita, Yoshito Terai, Junzo Kigawa, Toru Sugiyama, Daisuke Aoki

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 20 ( 5 ) 794 - 797 2010年7月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：LIPPINCOTT WILLIAMS & WILKINS

Objectives: The purpose of this study was to evaluate the association of ABCF2 (adenosine triphosphate-binding cassette superfamily F2) protein expression with response to chemotherapy and prognosis in patients with clear cell adenocarcinoma (CCC) of the ovary.Methods: One hundred sixty-five patients with CCC were studied, and cytoplasmic ABCF2 expression was detected by immunohistochemical staining. All patients underwent platinum-based primary chemotherapy followed by primary surgery.Results: Adenosine triphosphate-binding cassette superfamily F2 expression was detected in 118 (71.5%) of 165 patients and was not related to age or clinical stage. The response rate to chemotherapy in 38 patients with measurable disease was 47.3% (18/38). The response rate tended to be higher in patients without ABCF2 expression than in those with ABCF2 expression; however, this difference was not significant (66.7% vs 34.8%, P = 0.096). There was no significant difference in overall survival between ABCF2-positive and ABCF2-negative cases (median survival time, 1175 vs 1257 days; P = 0.24).Conclusions: Adenosine triphosphate-binding cassette superfamily F2 protein was highly expressed in CCC of the ovary, but expression was not related to age, clinical stage, chemoresponse, or prognosis.

DOI： 10.1111/IGC.0b013e3181a835fc

Web of Science

researchmap

Relationship between ABCF2 expression and response to chemotherapy or prognosis in clear cell adenocarcinoma of the ovary. 国際誌

Hiroshi Tsuda, Kiyoshi Ito, Nobuo Yaegashi, Akira Hirasawa, Tamotsu Sudo, Tsunekazu Kita, Yoshito Terai, Junzo Kigawa, Toru Sugiyama, Daisuke Aoki

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20 ( 5 ) 794 - 7 2010年7月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：LIPPINCOTT WILLIAMS & WILKINS

OBJECTIVES: The purpose of this study was to evaluate the association of ABCF2 (adenosine triphosphate-binding cassette superfamily F2) protein expression with response to chemotherapy and prognosis in patients with clear cell adenocarcinoma (CCC) of the ovary. METHODS: One hundred sixty-five patients with CCC were studied, and cytoplasmic ABCF2 expression was detected by immunohistochemical staining. All patients underwent platinum-based primary chemotherapy followed by primary surgery. RESULTS: Adenosine triphosphate-binding cassette superfamily F2 expression was detected in 118 (71.5%) of 165 patients and was not related to age or clinical stage. The response rate to chemotherapy in 38 patients with measurable disease was 47.3% (18/38). The response rate tended to be higher in patients without ABCF2 expression than in those with ABCF2 expression; however, this difference was not significant (66.7% vs 34.8%, P = 0.096). There was no significant difference in overall survival between ABCF2-positive and ABCF2-negative cases (median survival time, 1175 vs 1257 days; P = 0.24). CONCLUSIONS: Adenosine triphosphate-binding cassette superfamily F2 protein was highly expressed in CCC of the ovary, but expression was not related to age, clinical stage, chemoresponse, or prognosis.

DOI： 10.1111/IGC.0b013e3181a835fc

<平沢 晃>

論文 - 平沢 晃

<平沢　晃>

論文 - 平沢　晃